Bristol-Myers Squibb Co.

NYSE:BMY   11:47:52 AM EDT
68.50
+0.01 (+0.02%)
Products, Strategic Combinations

Eisai And Bristol Myers Squibb Enter Into Global Strategic Collaboration For Eisai’S Morab-202 Antibody Drug Conjugate

Published: 06/17/2021 22:37 GMT
Bristol-Myers Squibb Co. (BMY) - Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s Morab-202 Antibody Drug Conjugate.
Bristol-myers Squibb Co - Companies Are Planning to Move Into Registrational Stage of Development for This Asset As Early As Next Year.
Bristol-myers Squibb Co - Eisai Will Remain Responsible for Manufacturing and Supply of Morab-202 Globally.
Bristol-myers Squibb Co - Co Will Pay $650 Million to Eisai Including $200 Million As Payment Toward Eisai Research and Development Expenses.
Bristol-myers Squibb Co - Bristol Myers Squibb is Expected to Book Sales of Morab-202 in United States and Canada.
Bristol-myers Squibb Co - Eisai Also Entitled to Receive Up to $2.45 Billion USD in Potential Future Development, Regulatory, Commercial Milestones.
Bristol-myers Squibb Co - Eisai is Expected to Book Sales of Morab-202 in Japan, China, Countries in Asia-pacific Region, Europe and Russia.
Bristol-myers Squibb Co - Co & Eisai Will Share Profits, Research and Development and Commercialization Costs in Collaboration Territories.
Bristol-myers Squibb Co - Bristol Myers Squibb Will Pay Eisai a Royalty on Sales Outside of Collaboration Territories.